ZIM LABORATORIES LIMITED Intrinsic Value
ZIMLAB · Healthcare · Current price ₹121
Is ZIM LABORATORIES LIMITED undervalued?
DocStoX estimates the fair value of ZIM LABORATORIES LIMITED at ₹45 per share, versus the current market price of ₹121. That puts the stock about -63.1% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is high.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹48), Relative P/E (₹42), Graham floor (₹37). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹37 (bear) to ₹45 (base) to ₹51 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹121 versus an intrinsic value of ₹45, ZIM LABORATORIES LIMITED currently offers -63.1% of negative margin (i.e. a premium).
More on ZIM LABORATORIES LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.